Scientific | Commercial Analytics : HEOR (Health Economics and Outcomes Research)
Drive healthcare quality and costs with data.
Health technology assessments (HTA) to reimburse a new health technology typically encompass an economic analysis. Pharmaceutical manufacturers must demonstrate the clinical and economic evidences of products to gain market access and remain competitive. Economic evidence is often generated by evaluating both costs and outcomes to prove the efficiency of a product.
phamax HEOR services generate relevant evidence for products to communicate their value to stakeholders.
Systematic literature reviews and meta-analysis:
Our systematic literature review services answer all the important questions on efficacy, safety, quality of life and resource use. phamax follows the PRISMA guidelines, and defines the scope of projects, submits protocols, identifies databases and shortlists articles. The phamax HEOR team critically appraises relevant research and analyzes data from studies to answer research questions and perform meta-analysis, when required
Patient Reported Outcomes (PRO)
phamax PRO studies demonstrate how a therapy can affect a patient. phamax designs studies to capture the patient perspectives on a disease/treatment under different scenarios – clinical (e.g. cure, survival), humanistic (e.g. role performance, emotional status) and economical (e.g. expenses, saving).
Economic Evaluations:
- Cost-effectiveness analysis (CEA)
- Cost-utility analysis (CUA)
- Budget-impact analysis (BIA)
- Burden of disease or Illness/Economic impact analysis
Our models estimate the costs and outcomes of interventions, and compare different interventions impacting the same health effects (usually measured as life years gained) and different health effects (usually measured as utility-based outcome units (QALYs)). HEOR models for economic evaluations are the new normal for favorable reimbursement decisions.
The phamax HEOR service suite demonstrates the cost-effectiveness of the product vs. competition to support reimbursement submissions and highlight the incremental effectiveness of products at multiple price points.
- Synthesis of systematically-derived data for clinical and economic analyses
- Support reimbursement decisions by evaluating the clinical and economic impact of products
- Understand the impact of technologies in a real-life context and comprehend the needs and preferences of patients
- Understand the quality of life aspects and measure the burden of the disease by incorporating all the costs associated with the disease/intervention
- Evaluate the long-term effects (length and quality of life) of an intervention on health outcomes and ease the comparison of costs and outcomes of different interventions
- Determine the impact of implementing or adopting a particular technology on a designated budget
